Apathy in persons with Alzheimer's disease: An overview

Alzheimer's Care Today

Volumn 11, Issue 4, 2010, Pages 251-259

  Kim, Kye Y ^a   Detweiler, Mark B ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Apathy; Caregiving; Neuropsychiatric symptoms

Indexed keywords

EID: 77958067968     PISSN: 19363001     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACQ.0b013e3181f8bbaa     Document Type: Review

References (81)

1. Marin RS. Differential diagnosis and classification of apathy. Am J Psychiatry. 1990; 147: 22-30.
2. Petry S, Cummings JL, Hill MA, Shapira J. Personality alterations in dementia of Alzheimer type: a three- year follow-up. J Geriatr Psychiatry Neurol. 1989; 2: 203-207.
3. Lavretsky H, Ballmaier M, Phani D, Toga A, Kumar A. Neuroanatomical characteristics of geriatric apathy and depression: a magnetic resonance imaging study. Am J Geriatr Psychiatry. 2007; 15: 386-394.
4. Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991; 3: 243-254.
5. Starkstein SE, Jorge R, Mizrah R. The prevalence, clinical correlates and treatment of apathy in Alzheimer's disease.Eur JPsychiat. 2006; 20: 96-106.
6. Craig AH, Cummings JL, Fairbanks L, et al. Cerebral blood flow correlates of apathy in Alzheimer's disease. Arch Neurol. 1996; 53: 1116-1120.
7. Hargrave R, Geck LC, Reed B, Mungas D. Affective behavioral disturbances in Alzheimer's disease and ischemic vascular disease. J Neurol Neurosurg Psychiatry. 2000; 68: 41-46.
8. Paulsen JS, Stout JC, DeLaPena JH, et al. Frontal behavioral syndromes in cortical and subcortical dementia. Assessment. 1996; 3: 327-337.
9. Landes AM, Sperry SD, Strauss ME, Geldmacher DS. Apathy in Alzheimer's disease. J Am Geriatr Soc. 2001; 49: 1700-1707.
10. Arrighi HM, Neumann PJ, Lieberburg IM, Townsend RJ. Lethality of Alzheimer's disease and its impact on nursing home placement. Alzheimer Dis Assoc Disord. 2010; 24: 90-95.
11. Blakemore SJ, Winston J, Frith U. Social cognitive neuroscience: where are we heading? Trends Cogn Sci. 2004; 8: 216-222.
12. Courchesne E, chisum HJ, Townsend J, et al. Normal brain development and aging: quantitative analysis at in vivo MR imaging in healthy volunteers. Radiology. 2000; 216: 672-682.
13. Sowell ER, Peterson BS, Thompson PM, et al. Mapping cortical changes across the human life span. Nature Neurosci. 2003; 6: 309-315.
14. Rosen HJ, Allison SC, Schauer GF, Gorno-Tempini ML, Weiner MW, Miller BL. Neuroanatomical correlates of behavioral disorders in dementia. Brain. 2005; 128: 2612-2625.
15. Thompson PM, Apostolova LG. Computational anatomical methods as applied to ageing and dementia. Br J Radiol. 2007; 80: S78-S91.
16. Robert PH, Darcourt G, Koulibaly MP, et al. Lack of initiative and interest in Alzheimer's disease: a single photon emission computed tomography study. Eur J Neurol. 2006; 13: 729-735.
17. Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol. 1993; 50: 873-880.
18. Migneco O, Benoit M, Koulibaly PM, et al. Perfusion brain SPECT and statistical parametric mapping analysis indicate that apathy is a cingulated syndrome: a study in Alzheimer's disease and nonde- mented patients.Neuroimage. 2001; 13: 896-902.
19. Malloy PF, Boyle PA. Apathy and its treatment in Alzheimer's disease and other dementias. Psychiatr Times. 2005; 23. http://www.psychiatrictimes.com/ display/article/10168/52691?pageNumber=3. Accessed July 11, 2009.
20. Erixon-Lindroth N, Farde L, Wahlin TB, Sovago J, Halldin C, Backman L. The role of the striatal dopamine transporter in cognitive aging. Psychiatry Res. 2005; 138: 1-12.
21. David R, Koulibaly M, Benoit M, et al. Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases: a SPECT study with partial volumetric effect correlation. Clin Neurol Neurosurg. 2008; 110: 19-24.
22. Holthoff VA, Beuthian-Baumann B, Kalbe E, et al. Regional cerebral metabolism in early Alzheimer's disease with clinically significant apathy or depression. Biol Psychiatry. 2005; 57: 412-421.
23. Benoit M, Koulibaly PM, Migneco O, et al. Brain perfusion in Alzheimer's disease with and without apathy: a SPECT study with statistical parametric mapping analysis.Psychiatry Res. 2002; 114: 103-111.
24. Tekin S, Mega MS, Masterman DM, et al. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden in associated with agitation in Alzheimer's disease.Ann Neurol. 2001; 49: 355-361.
25. Marshall GA, Fairbanks LA, Tekin S, Vinters HV Cummings JL. Neuropathologic correlates of apathy in Alzheimer's disease. Demen Geriatr Cogn Disord. 2006; 21: 144-147.
26. Apostolova LG, Akopyan GG, Partiali N, et al. Structural correlates of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord. 2007; 24: 91-97.
27. Mega MS, Dinov ID, Porter V et al. Metabolic patterns associated with the clinical response to galan- tamine therapy: a fludeoxyglucose f-18 positron emission tomography study. Arch Neurol. 2005; 62: 721-728.
28. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Text Revision (DSM-IV-TR). 4th ed. Washington, DC: American Psychiatric Association; 2000.
29. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders. Geneva, Switzerland: World Health Organization; 1993.
30. Robert P, Onyike CU, Leentjens AF, et al. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry. 2009; 24: 98-104.
31. Marin RS. Apathy and related disorders of diminished motivation. In: Dickstein LJ, Riba MB, Oldham JM, eds. Review of Psychiatry. Vol 15. Washington, DC: American Psychiatric Press; 1996: 205-242.
32. Starkstein SE. Apathy and withdrawal. Int Psychogeriatr. 2000; 12(suppl 1): 135-138.
33. Marin RS, Wilkosz PA. Disorders of diminished motivation. J Head Trauma Rehabil. 2005; 20: 377-388.
34. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology. 1996; 46: 130-135.
35. Treiber KA, Lyketsos CG, Corcoran C, et al. Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study. Int Psychogeriatr. 2008; 20: 538-553.
36. Robinson RG, Szetela B. Mood changes following left hemisphere brain injury. Ann Neurol. 1981; 9: 447-453.
37. Robinson RG, Kubos KL, Starr LB, Rao K, Price TR. Mood disorders in stroke patients: importance of location of lesion. Brain. 1984; 107: 81-93.
38. Levy ML, Miller BL, Cummings JL, Fairbanks LA, Craig A. Alzheimer's disease and frontotemporal dementia. Behavioral distinctions. Arch Neurol. 1996; 53: 687-690.
39. Litvan I, Mega MS, Cummings JL, Fairbanks LA. Neuropsychiatric aspects of progressive supranuclear palsy. Arch Neurol. 1997; 54: 350.
40. Ready RE, Ott BR, Grace J, Cahn-Weiner DA. Apathy and executive dysfunction in mild cognitive impairment and Alzheimer's disease. Am J Geriatr Psychiatry. 2003; 11: 222-228. (Pubitemid 36254196)
41. Mayberg HS, Brannan SK, Mahurin RK, et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport. 1997; 8: 1057-1061.
42. Levy ML, Cummings JL, Fairbanks LA, et al. Apathy is not depression. J Neuropsychiatry Clin Neurosci. 1998; 10: 314-319.
43. Cummings JL. Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neuro- biological basis. Neurobiol Aging. 2000; 21: 845-861.
44. Frisoni GB, Pievani M, Testa C, et al. The tomography of grey matter involvement in early and late onset Alzheimer's disease. Brain. 2007; 130: 720-730.
45. Marin RS, Butters MA, Mulsant BH, Pollock BG, Reynolds CF. Apathy and executive function in depressed elderly. J Geriatr Psychiatry Neurol. 2003; 16: 112-116.
46. Marin RS, Firinciogullari S, Biedrzycki RC. Group differences in the relationship between apathy and depression. J Nerv Ment Dis. 1994; 182: 235-239.
47. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1992; 4: 134-139.
48. Starkstein SE, Migliorelli R, Manes F, et al. The prevalence and clinical correlates of apathy and irritability in Alzheimer's disease. Eur J Neurol. 1995; 2: 54-546.
49. Strauss ME, Sperry SD. An informant-based assessment of apathy in Alzheimer's disease. Neuropsychiatry Neuropsychol Behav Neurol. 2002; 15: 176-183.
50. Robert PH, Clairet S, Benoit M, et al. The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease, and mild cognitive impairment. Int J Geriatr Psychiatry. 2002; 17: 1099-1105.
51. Cummings JL. The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology. 1997; 48(suppl 6): S10-S16.
52. Starkstein SE, Petracca G, Chemerinski E, Kremer J. Syndromic validity of apathy in Alzheimer's disease. Am J Psychiatry. 2001; 158: 872-877.
53. Lueken U, Seidi U, Volker L, Schweiger E, Kruse A, Schroder J. Development of a short version of apathy evaluation scale specifically adapted for demented nursing home residents. Am J Geriatr Psychiatry. 2007; 15: 376-385.
54. Sockeel IP Dujardin K, Devos D, Deneve C, Destee A, Defebvre L. The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease. J Neurol Neu- rosurg Psychiatry. 2006; 77: 579-584.
55. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44: 2308-2314.
56. Chung JA, Cummings JL. Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment. Neurol Clin. 2000; 18: 829-846.
57. Teri L. Behavior and caregiver burden: behavioral problems in patients with Alzheimer's disease and its association with caregiver distress. Alzheimer Dis Assoc Disord. 1997; 11(suppl 4): S35-S38.
58. Freels S, Cohen D, Eisdorfer C, et al. Functional status and clinical findings in patients with Alzheimer's. J Gerontol. 1992; 47: M177-M182.
59. Boyle PA, Malloy PF. Salloway S, Cahn-Weiner DA, Cohen R, Cummings JL. Executive dysfunction and apathy predict functional impairment in Alzheimer's disease. Am J Geriatr Psychiatry. 2003; 11: 214-221.
60. Greene JG, Smith R, Gardiner M, Timbury GC. Measuring behavioral disturbance of elderly demented patients in the community and its effect on relative: a factor analytic study. Age Ageing. 1982; 11: 121-126.
61. Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease. The Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998; 46: 210-215.
62. Drijgers RL, Aalten P, Winogrodzka A, Verhey FR, Leentjens AF. Pharmacological treatment of apathy in neurodegenerative diseases: a systematic review. Dement Geriatr Cogn Disord. 2009; 28: 13-22.
63. Corcoran C, Wong ML, O'Keane V. Bupropion in the management of apathy. J Psychopharmacol. 2004; 18: 133-135.
64. Padala PR, Burke WJ, Bhatia SC. Modafinil therapy for apathy in an elderly patient. Ann Pharmacother. 2007; 41: 346-349.
65. Catsman-Berrevoets CE, von Harskamp F. Compulsive pre-sleep behavior and apathy due to bilateral thalamic stroke: response to bromocriptine. Neurology. 1988; 38: 647-649.
66. Chatterjee A, Fahn S. Methylphenidate treats apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2002; 14: 461-462.
67. Galynker I, Leronimo C, Miner C, et al. Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci. 1997; 9: 231-239. (Pubitemid 27198799)
68. Janse IH, Olde Rikkert MG, Hulsbos HA, Hoefnagels WH. Toward individualized evidence-based medicine: five "N of 1" trials of methylphenidate in geriatric patients. J Am Geriatr Soc. 2001; 49: 474-476.
69. Padala PR, Bhatia SC, Burke WJ. Open label treatment of apathy in dementia of Alzheimer type with methylphenidate. J Am Geriatr. 2006; 54: S52.
70. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry. 2003; 11: 131-145.
71. Wynn ZJ, Cummings JL. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. 2004; 17: 100-108.
72. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2003; (3): CD001190 (update).
73. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2000; (4): CD001191 (update).
74. Dartigues JF, Goulley F, Bourdeix I, Pere JJ, Barberger-Gateau P. Rivastigmine in current clinical practice in patients with mild to moderate dementia. Rev Neurol. 2002; 158: 807-812.
75. Cummings JL, Koumaras B, Chen M, Mirski D; Rivastigmine Nursing Home Study Team. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open- label study. Am J Geriatr Pharmacother. 2005; 3: 137-148.
76. Holmes C, Knights A, Dean C, Hodkinson S, Hopkins V. Keep music live: music and the alleviation of apathy in dementia. Int Psychogeriatr. 2006; 18: 623-630.
77. Tondi L, Ribani L, Bottazzi M, Viscomi G, Vulcano V. Validation therapy (VT) in nursing home: a casecontrol study. Arch Gerontol Geriatr. 2007; 44 (suppl 1): 407-411.
78. Overshott R, Byrne J, Bums A. Nonpharmacological interventions for symptoms in Alzheimer's disease. Expert Rev Neurother. 2004; 4: 809-821.
79. Politis AM, Vozzella S, Mayer LS, Onyike CU, Baker AS, Lyketsos CG. A randomized, controlled, clinical trial of activity therapy for apathy in patients with dementia residing in long-term care unit. Int J Geriatr Psychiatry. 2004; 19: 1087-1094.
80. Boyle PA, Malloy PF. Treating apathy in Alzheimer's disease. Dement Geriatr Cogn Disord. 2004; 17: 91-99.
81. Lund DA, Hill RD, Caserta MS, Wright SD. Video respite: an innovative resource for family, professional caregivers, and persons with dementia. Gerontologist. 1995; 35: 683-687.